TSX:ONC 1.43 CAD -0.03 -2.06% Volume: 14,003 August 1, 2014
NASDAQ:ONCY 1.32 USD -0.02 -1.49% Volume: 71,062 August 1, 2014

A Novel Approach to Cancer Therapeutics

Oncolytics Biotech is a biotechnology company focused on the development of oncolytic viruses as potential therapeutics for use in a broad range of cancers. The Company is conducting clinical studies using REOLYSIN®, its proprietary formulation of the human reovirus, in some of the most prevalent forms of the disease including lung, colorectal and pancreatic cancers. Oncolytics’ clinical program includes a number of human trials at a variety of stages including a Phase III trial in head and neck cancers. The Company has advanced its product manufacturing and intellectual property initiatives in parallel with its clinical development program to support development of a commercial product.

Latest News

July 08, 2014 Oncolytics Biotech® Inc. Announces Completion of Patient Enrollment in U.S. Randomized Phase II Pancreatic Cancer Study
June 19, 2014 Oncolytics Biotech® Inc. Announces Director Election Results from its Annual Meeting of Shareholders
June 16, 2014 Oncolytics Biotech® Inc. Announces Details of 2014 Annual Meeting of Shareholders
Sign up to receive e-mail updates *